Ranbaxy falls around 16 pct after FDA bans products

MUMBAI (Reuters) - Shares in Ranbaxy Laboratories Ltd, majority owned by Japan's Daiichi Sankyo Co Ltd<4568.T>, slumped around 16 percent in early trade after the U.S. Food and Drug Administration banned more products from the Indian drugmaker.

The FDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa, India, "to prevent substandard quality products from reaching U.S. consumers."

(Reporting by Abhishek Vishnoi; Editing by Rafael Nam)